ResearcherETH ZurichNo recent work listed

Markus Stoffel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-1304-5817; OpenAlex author ID A5016377862. Sources: OpenAlex.

Their work

Papers: 5 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 11

Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper · 2023: 3 papers

Papers 5

Mass Spectrometry Reveals High Levels of Hydrogen Peroxide in Pancreatic Cancer Cells. Co-author DOI 10.1002/anie.202213703 ↗
Genetic ablation of ketohexokinase C isoform impairs pancreatic cancer development. Last author DOI 10.1016/j.isci.2023.107368 ↗
Mutant SF3B1 promotes malignancy in PDAC. Co-author DOI 10.7554/elife.80683 ↗
SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. Co-author DOI 10.1016/j.celrep.2022.111266 ↗
High-Throughput Single-Cell Mass Spectrometry Reveals Abnormal Lipid Metabolism in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/anie.202107223 ↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Gerald Schwank · 3 shared papers, 2022–2023 · strength 0.43
Qinlei Liu · 2 shared papers, 2021–2023 · strength 0.34
- Paper Mass Spectrometry Reveals High Levels of Hydrogen Peroxide in Pancreatic Cancer Cells. DOI 10.1002/anie.202213703 ↗
- Paper High-Throughput Single-Cell Mass Spectrometry Reveals Abnormal Lipid Metabolism in Pancreatic Ductal Adenocarcinoma. DOI 10.1002/anie.202107223 ↗
Renato Zenobi · 2 shared papers, 2021–2023 · strength 0.34
- Paper Mass Spectrometry Reveals High Levels of Hydrogen Peroxide in Pancreatic Cancer Cells. DOI 10.1002/anie.202213703 ↗
- Paper High-Throughput Single-Cell Mass Spectrometry Reveals Abnormal Lipid Metabolism in Pancreatic Ductal Adenocarcinoma. DOI 10.1002/anie.202107223 ↗
Gunnar Rätsch · 2 shared papers, 2022–2023 · strength 0.27
- Paper Mutant SF3B1 promotes malignancy in PDAC. DOI 10.7554/elife.80683 ↗
- Paper SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. DOI 10.1016/j.celrep.2022.111266 ↗
Patrik Simmler · 2 shared papers, 2022–2023 · strength 0.27
- Paper Mutant SF3B1 promotes malignancy in PDAC. DOI 10.7554/elife.80683 ↗
- Paper SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. DOI 10.1016/j.celrep.2022.111266 ↗
Ilaria Guccini · 2 shared papers, 2022–2023 · strength 0.26
- Paper Genetic ablation of ketohexokinase C isoform impairs pancreatic cancer development. DOI 10.1016/j.isci.2023.107368 ↗
- Paper SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. DOI 10.1016/j.celrep.2022.111266 ↗
Solange Le Blanc · 1 shared paper, 2023 · strength 0.15
- Paper Genetic ablation of ketohexokinase C isoform impairs pancreatic cancer development. DOI 10.1016/j.isci.2023.107368 ↗
Oliver Strobel · 1 shared paper, 2023 · strength 0.15
- Paper Genetic ablation of ketohexokinase C isoform impairs pancreatic cancer development. DOI 10.1016/j.isci.2023.107368 ↗
Chantal Pauli · 1 shared paper, 2022 · strength 0.11
- Paper SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. DOI 10.1016/j.celrep.2022.111266 ↗
Daniela M. Lenggenhager · 1 shared paper, 2022 · strength 0.11
- Paper SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. DOI 10.1016/j.celrep.2022.111266 ↗
Christian Hirt · 1 shared paper, 2022 · strength 0.11
- Paper SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. DOI 10.1016/j.celrep.2022.111266 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.